Biopharma Dealmaking Quarterly Statistics, Q3 2014
A look at financing, M&A, and alliance activity July–September 2014
Executive Summary
Biopharma financing dropped 22% in Q3 to $5.65 billion. In the largest M&A, Roche bulked up on rare diseases, gaining Esbriet through its $8 billion takeover of InterMune; Sanofi dominated in alliance dealmaking.